CytochromeP450 isoenzyme specificity in the metabolism of anti-malarial biguanides: Molecular docking and molecular dynamics analyses

Medicinal Chemistry Research

Volumn 21, Issue 12, 2012, Pages 4274-4289

  Patel, Dhilon S ^a   Ramesh, M ^a   Bharatam, Prasad V ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Biguanides; CytochromeP450; Molecular docking; Molecular dynamics

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DRUG METABOLITE; JPC 1084; JPC 2005; JPC 2028; JPC 2056; JPC 2058; JPC 2059; N [3 (2,4,5 TRICHLOROPHENOXY)PROPOXY] N' ISOPROPYLIMIDOCARBONIMIDIC DIAMIDE; PROGUANIL; PS 26; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; DRUG DEVELOPMENT; DRUG PROTEIN BINDING; DRUG STRUCTURE; IN VITRO STUDY; MOLECULAR DOCKING; MOLECULAR DYNAMICS;

EID: 84855493219     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-011-9966-9     Document Type: Article

References (67)

1. Bajwa BS, Acton N, Brossi A (1983) The chemistry of drugs. III. Acid hydrolysis of antimalarial 5-alkoxy-6,6-dimethyl-5,6-dihydro-s-triazines. Heterocycles 20:839-843
2. Bharatam PV, Patel DS, Iqbal P (2005) Pharmacophoric features of biguanide derivatives: an electronic and structural analysis. J Med Chem 48:7615-7622
3. Birkett DJ, Rees D, Andersson T, Gonzalez FJ, Miners JO, Veronese ME (1994) In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase. Br J Clin Pharmacol 37:413-420
4. Biswas S (2001) Plasmodium falciparum dihydrofolate reductase Val-16 and Thr-108 mutation associated with in vivo resistance to antifolate drug: a case study. Indian J Malariol 38:76-83
5. Black RH (1946) The effect of anti-malarial drugs on Plasmodium falciparum (New Guinea Strains) developing in vitro. Trans R Soc Trop Med Hyg 40:163-170
6. Butler R, Davey DG, Spinks A (1947) A preliminary report of the toxicity and the associated blood concentrations of paludrine in laboratory animals. Br J Pharmacol Chemother 2:181-188
7. Canfield CJ (1986) New antimalarials under development. In: Bruce-Chatt LJ (ed) Chemotherapy of malaria. Monograph series 27, 2nd edn. World Health Organization, Geneva, pp 99-100
8. Canfield CJ, Milhous WK, Ager AL, Rossan RN, Sweeney TR, Lewis NJ, Jacobus DP (1993) PS-15: A potent, orally active antimalarial from a new class of folic acid antagonists. Am J Trop Med Hyg 49:121-126
9. Carrington HC, Crowther AF, Davey DG, Levi AA, Rose FL(1951) A metabolite of paludrine with high antimalarial activity. Nature 168:1080
10. Coller JK, Somogyi AA, Bochner F (1999) Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms. Br J Clin Pharmacol 48:158-167
11. Crowther AF, Levi AA (1953) Proguanil—the isolation of a metabolite with high anti-malarial activity. Br J Pharmacol Chemother 8:93-97
12. Curtis J, Maxwell CA, Msuya FHM, Mkongewa S, Alloueche A, Warhurst DC (2002) Mutations in DHFR in Plasmodium falciparum infections selected by chlorproguanil-dapsone treatment. J Infect Dis 186:1861-1864
13. Dasgupta T, Chitnumsub P, Kamchonwongpaisan S, Maneeruttanarungroj C, Nichols SE, Lyons TM, Tirado-Rives J, Jorgensen WL, Yuthavong Y, Anderson KS (2009) Exploiting structural analysis, in silico screening, and serendipity to identify novel inhibitors of drug-resistant falciparum malaria. ACS Chem Biol 4:29-40
14. Delfino RT, Santos-Filho OA, Figueroa-Villar JD (2002) Molecular modeling of wild-type and antifolate resistant mutant Plasmodium falciparum DHFR. Biophys Chem 98:287-300
15. Desmond (2009) Version 2.2, Schrödinger, LLC, New York, NY
16. Desta Z, Zhao X, Shin JG, Flockhart DA (2002) Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41:913-958
17. Diaz DS, Kozar MP, Smith KS, Asher CO, Sousa JC, Schiehser GA, Jacobus DP, Milhous WK, Skillman DR, Shearer TW (2008) Role of specific P450 isoforms in the conversion of phenoxypropoxybiguanide analogs in human liver microsomes to potent antimalarial dihydrotriazines. Drug Metab Dispos 36:380-385
18. Edstein MD, Bahr S, Kotecka B, Shanks GD, Rieckmann KH (1997) In vitro activities of the biguanide PS-15 and its metabolite, WR99210, against cycloguanil-resistant Plasmodium falciparum isolates from Thailand. Antimicrob Agents Chemother 41:2300-2301
19. Ekroos M, Sjögren T (2006) Structural basis for ligand promiscuity in cytochrome P450 3A4.
20. Proc Natl Acad Sci USA 103:13682-13687
21. Eskandarian AA, Keshavarz H, Basco LK, Mahboudi F (2002) Do mutations in Plasmodium falciparum dihydropteroate synthase and dihydrofolate reductase confer resistance to sulfadoxinepyrimethamine in Iran? Trans R Soc Trop Med Hyg 96:96-98
22. Essman U, Perera L, Berkowitz ML, Darden T, Lee H, Pedersen LG (1995) A smooth particle mesh Ewald method. J Chem Phys 103:8577-8593
23. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P, Shenkin PS (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47:1739-1749
24. Frisch MJ, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Zakrzewski VG, Montgomery JA Jr, Stratmann RE, Burant JC, Dapprich S, Millam JM, Daniels AD, Kudin KN, Strain MC, Farkas O, Tomasi J, Barone V, Cossi M, Cammi R, Mennucci B, Pomelli C, Adamo C, Clifford S, Ochterski J, Petersson GA, Ayala PY, Cui Q, Morokuma K, Malick DK, Rabuck AD, Raghavachari K, Foresman JB, Cioslowski J, Ortiz JV, Baboul AG, Stefanov BB, Liu G, Liashenko A, Piskorz P, Komaromi I, Gomperts R, Martin RL, Fox DJ, Keith T, Al-Laham MA, Peng CY, Nanayakkara A, Gonzalez C, Challacombe M, Gill PMW, Johnson B, Chen W, Wong MW, Andres JL, Gonzalez C, Head-Gordon M, Replogle ES, Pople JA (2004) Gaussian 03 Revision C.02. Gaussian, Inc., Wallingford, CT
25. Funck-Brentano C, Becquemont L, Lenevu A, Roux A, Jaillon P, Beaune P (1997) Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments. J Pharmacol Exp Ther 280:730-738
26. Gemma S, Travagli V, Savini L, Novellino E, Campiani G, Butini S (2010) Malaria chemotherapy: recent advances in drug development. Recent Pat Antiinfect Drug Discov 5:195-225
27. Greenwood BM, Bojang K, Whitty CJ, Targett GA (2005) Malaria. Lancet 365:1487-1498
28. Greenwood BM, Fidock DA, Kyle DE, Kappe SH, Alonso PL, Collins FH, Duffy PE (2008) Malaria: progress, perils, and prospects for eradication. J Clin Invest 118:1266-1276
29. Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, Banks JL (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 47:1750-1759
30. Hawking F, Perry WLM (1948) Activation of pauldrine. Br J Pharmacol Chemother 3:320-325
31. Helsby NA (2008) Pheno-or genotype for the CYP2C19 drug metabolism polymorphism: the influence of disease. Proc West Pharmacol Soc 51:5-10
32. Helsby NA, Ward SA, Edwards G, Howells RE, Breckenridge AM (1990a) The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. Br J Clin Pharmacol 30:593-598
33. Helsby NA, Ward SA, Howells RE, Breckenridge AM (1990b) In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme. Br J Clin Pharmacol 30:287-291
34. Hritz J, de Ruiter A, Oostenbrink C (2008) Impact of plasticity and flexibility on docking results for cytochrome P450 2D6: a combined approach of molecular dynamics and ligand docking. J Med Chem 51:7469-7477
35. Ingelman-Sundberg M (2005) Genetic polymorphisms of cytochromeP450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5:6-13
36. Ito Y, Kondo H, Goldfarb PS, Lewis DFV (2008) Analysis of CYP2D6 substrate interactions by computational methods. J Mol Graph Model 26:947-956
37. Jensen NP, Ager AL, Bliss RA, Canfield CJ, Kotecka BM, Rieckmann KH, Terpinski J, Jacobus DP (2001) Phenoxypropoxybiguanides, prodrugs of DHFR inhibiting diaminotriazine antimalarials. J Med Chem 44:3925-3931
38. Jones G, Willett P, Glen RC, Leach AR, Taylor R (1997) Development and validation of a genetic algorithm for flexible docking. J Mol Biol 267:727-748
39. Jorgensen WL, Tirado-Rives J (1988) The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. J Am Chem Soc 110:1657-1666
40. Jorgensen WL, Maxwell DS, Tirado-Rives J (1996) Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc 118:11225-11236
41. Jurima M, Inaba T, Kadar D, Kalow W (1985) Genetic polymorphism of mephenytoin p(40)-hydroxylation: difference between Orientals and Caucasians. Br J Clin Pharmacol 19:483-487
42. Kaump DH, Schardein JL, Fisken RA, Sorenson OJ (1965) Toxicity of the repository antimalarial compound cycloguanil pamoate. Toxicol Appl Pharmacol 7:781-793
43. Le Bras J, Durand R (2003) The mechanisms of resistance to antimalarial drugs in Plasmodium falciparum. Fundam Clin Pharmacol 17:147-153
44. Leach AR (2001) Molecular modelling: principles and applications, 2nd edn. Prentice Hall, Englewood Cliffs, NJ
45. Lu AH, Shu Y, Huang SL, Wang W, Ou-Yang DS, Zhou HH (2000) In vitro proguanil activation to cycloguanil is mediated by CYP2C19 and CYP3A4 in adult Chinese liver microsomes. Acta Pharmacol Sin 21:747-752
46. Martyna GJ, Tobias DJ, Klein ML (1994) Constant pressure molecular dynamics algorithms. J Chem Phys 101:4177-4189
47. McCammon JA, Harvey SC (1987) Dynamics of proteins and nucleic acids. Cambridge University Press, Cambridge
48. Na-Bangchang K, Manyando C, Ruengweerayut R, Kioy D, Mulenga M, Miller GB, Konsil J (2005) The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. Eur J Clin Pharmacol 61:573-582
49. Nosten F, McGready R, d’Alessandro U, Bonell A, VerhoeffF, Menendez C, Mutabingwa T, Brabin B (2006) Antimalarial drugs in pregnancy: a review. Curr Drug Saf 1:1-15
50. Nyunt MM, Plowe CV (2007) Pharmacologic advances in the global control and treatment of malaria: combination therapy and resistance. Clin Pharmacol Ther 82:601-605
51. Rieckmann KH (1973) The in vitro activity of experimental antimalarial compounds against strains of Plasmodium falciparum with varying degrees of sensitivity to pyrimethamine and chloroquine, in chemotherapy of malaria and resistance to antimalarials. World Health Organization Technical Report Series. World Health Organization, Geneva, Switzerland
52. Rieckmann KH (2006) The chequered history of malaria control: are new and better tools the ultimate answer? Ann Trop Med Parasitol 100:647-662
53. Rieckmann KH, Yeo AE, Edstein MD (1996) Activity of PS-15 and its metabolite, WR99210, against Plasmodium falciparum in an in vivo-in vitro model. Trans R Soc Trop Med Hyg 90: 568-571
54. Satyanarayana CR, Devendran A, Jayaraman M, Mannu J, Mathur PP, Gopal SD, Rajagopal K, Chandrasekaran A (2009) Influence of the genetic polymorphisms in the 50 flanking and exonic regions of CYP2C19 on proguanil oxidation. Drug Metab Pharmacokinet 24:537-548
55. Shearer TW, Kozar MP, O’Neil MT, Smith PL, Schiehser GA, Jacobus DP, Diaz DS, Yang YS, Milhous WK, Skillman DR (2005) In vitro metabolism of phenoxypropoxybiguanide analogues in human liver microsomes to potent antimalarial dihydrotriazines. J Med Chem 48:2805-2813
56. Skopalík J, Anzenbacher P, Otyepka M (2008) Flexibility of human cytochromes P450: molecular dynamics reveals differences between CYPs 3A4, 2C9, and 2A6, which correlate with their substrate preferences. J Phys Chem B 112:8165-8173
57. Sridaran S, McClintock SK, Syphard LM, Herman KM, Barnwell JW, Udhayakumar V (2010) Anti-folate drug resistance in Africa: meta-analysis of reported dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) mutant genotype frequencies in African Plasmodium falciparum parasite populations. Malar J 9:247
58. Tonkin IM (1946) The testing of drugs against exoerythrocytic forms of P-gallinaceum in tissue culture. Br J Pharmacol Chemother 1:163-173
59. Warhurst DC (2002) Resistance to antifolates in Plasmodium falciparum, the causative agent of tropical malaria. Sci Prog 85: 89-111
60. Wattanagoon Y, Taylor RB, Moody RR, Ochekpe NA, Looareesuwan S, White NJ (1987) Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects. Br J Clin Pharmacol 24:775-780
61. Wiesner J, Ortmann R, Jomaa H, Schlitzer M (2003) New antimalarial drugs. Angew Chem Int Ed Engl 42:5274-5293
62. Wirth D (1998) Malaria: a 21st century solution for an ancient disease. Nat Med 4:1360-1362
63. Wirth DF (1999) Malaria: a third world disease in need of first world drug development. Annu Rep Med Chem 34:349-358
64. World Malaria Report (2009) World Health Organization, Geneva, Switzerland
65. Wright JD, Helsby NA, Ward SA (1995) The role of S-mephenytoin hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanides. Br J Clin Pharmacol 39:441-444
66. Yuthavong Y (2002) Basis for antifolate action and resistance in malaria. Microbes Infect 4:175-182
67. Yuvaniyama J, Chitnumsub P, Kamchonwongpaisan S, Vanichtanankul J, Sirawaraporn W, Taylor P, Walkinshaw MD, Yuthavong Y (2003) Insights into antifolate resistance from malarial DHFR-TS structures. Nat Struct Biol 10:357-365